miRNA-mediated metabolic reprogramming is associated with recurrence in ovarian cancer
EPIGENOMICS, cilt.18, sa.8, ss.951-963, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 18 Sayı: 8
- Basım Tarihi: 2026
- Doi Numarası: 10.1080/17501911.2026.2721124
- Dergi Adı: EPIGENOMICS
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Aerospace Database, Chemical Abstracts Core, EMBASE, MEDLINE, Natural Science Collection (ProQuest), Biological Science Database (ProQuest), Health Research Premium Collection (ProQuest), Pharma Collection (ProQuest), Technology Collection (ProQuest)
- Sayfa Sayıları: ss.951-963
- İstanbul Üniversitesi Adresli: Evet
Özet
Background: Ovarian cancer (OC) recurrence and therapy resistance remain major clinical challenges. Identifying the molecular adaptations associated with relapse is essential for improving disease monitoring. Research design and methods: We performed miRNA expression profiling on tissue and serum samples obtained from different primary ovarian cancer (POC) (n = 8) and recurrent ovarian cancer (ROC) cases (n = 8). Following statistical filtering, target prediction and functional pathway enrichment analyses were conducted. Clinical prognostic associations of target genes were explored using the Kaplan-Meier Plotter database. Results: A candidate recurrence-associated signature was identified, comprising hsa-miR-3656 (tissue, Fold Change >1.8), hsa-miR-4701-5p, and hsa-miR-6775-3p (serum, Fold Change >2.0), all significantly upregulated in ROC. Computational target analysis identified 375 miRNA-mRNA interactions primarily enriched in sphingolipid and purine metabolism pathways. Evaluation of the target genes indicated that altered expression of DEGS1, NPR1, and ALDH1B1 is correlated with poorer progression-free survival. Conclusions: OC recurrence is associated with a distinct miRNA profile linked to metabolic reprogramming. Although functional validation is required, circulating hsa-miR-4701-5p and hsa-miR-6775-3p represent candidate liquid biopsy biomarkers requiring prospective validation for recurrence monitoring.